logo
Vanguard Health Care Fund's Strategic Moves: Johnson & Johnson Takes Center Stage with 2. ...

Vanguard Health Care Fund's Strategic Moves: Johnson & Johnson Takes Center Stage with 2. ...

Yahoo4 days ago
Exploring the Latest Investment Strategies of Vanguard Health Care Fund (Trades, Portfolio)
Vanguard Health Care Fund (Trades, Portfolio) recently submitted its N-PORT filing for the second quarter of 2025, shedding light on its strategic investment decisions during this period. Managed by Jean M. Hynes, CFA, CEO of Wellington Management Company, the fund is renowned for its focus on long-term capital appreciation within the health care sector. Wellington Management Company, established in 1928, is one of the oldest and most respected institutional investment managers in the United States, advising the Vanguard Health Care Fund (Trades, Portfolio) since 1984. The fund aims to maintain a diversified exposure across five primary subsectors: health services, medical products, specialty pharmaceuticals, major pharmaceuticals, and international markets. Its investment philosophy emphasizes companies with robust balance sheets, strong management, and potential for innovative products that could drive above-average growth in revenue and earnings. The fund's contrarian style often leads to purchasing stocks after negative events have caused a decline in share price.
Summary of New Buy
Vanguard Health Care Fund (Trades, Portfolio) added a total of eight stocks, with the most significant addition being Johnson & Johnson (NYSE:JNJ). The fund acquired 4,660,244 shares, which now account for 2.05% of the portfolio, with a total value of $711.85 million. The second largest addition was Roche Holding AG (XSWX:ROG), consisting of 1,677,044 shares, representing approximately 1.58% of the portfolio, with a total value of CHF 547,420,130. The third largest addition was Gilead Sciences Inc (NASDAQ:GILD), with 4,823,087 shares, accounting for 1.54% of the portfolio and a total value of $534.74 million.
Key Position Increases
Vanguard Health Care Fund (Trades, Portfolio) also increased stakes in a total of 16 stocks. The most notable increase was in Elevance Health Inc (NYSE:ELV), with an additional 507,005 shares, bringing the total to 1,700,286 shares. This adjustment represents a significant 42.49% increase in share count, a 0.57% impact on the current portfolio, with a total value of $661.34 million. The second largest increase was in Cencora Inc (NYSE:COR), with an additional 501,886 shares, bringing the total to 2,279,215. This adjustment represents a significant 28.24% increase in share count, with a total value of $683.42 million.
Summary of Sold Out
Vanguard Health Care Fund (Trades, Portfolio) completely exited 12 holdings in the second quarter of 2025. Notable exits include Blueprint Medicines Corp (BPMC), where the fund sold all 1,362,970 shares, resulting in a -0.32% impact on the portfolio. Another significant exit was Surgery Partners Inc (NASDAQ:SGRY), with the liquidation of all 4,602,252 shares, causing a -0.29% impact on the portfolio.
Key Position Reduces
Vanguard Health Care Fund (Trades, Portfolio) also reduced its position in 45 stocks. The most significant changes include a reduction in Novartis AG (XSWX:NOVN) by 5,691,220 shares, resulting in a -49.44% decrease in shares and a -1.66% impact on the portfolio. The stock traded at an average price of CHF 93.19 during the quarter and has returned 8.24% over the past three months and 13.88% year-to-date. Another notable reduction was in Edwards Lifesciences Corp (NYSE:EW) by 6,663,224 shares, resulting in a -37.32% reduction in shares and a -1.27% impact on the portfolio. The stock traded at an average price of $74.55 during the quarter and has returned 2.89% over the past three months and 4.93% year-to-date.
Portfolio Overview
As of the second quarter of 2025, Vanguard Health Care Fund (Trades, Portfolio)'s portfolio included 81 stocks. The top holdings included 10.78% in Eli Lilly and Co (NYSE:LLY), 6.49% in AstraZeneca PLC (LSE:AZN), 5.56% in UnitedHealth Group Inc (NYSE:UNH), 4.52% in Merck & Co Inc (NYSE:MRK), and 4.35% in Boston Scientific Corp (NYSE:BSX). The holdings are mainly concentrated in one of the 11 industries: Healthcare.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Qualys (QLYS) Wins Two Pwnie Awards at DEF CON for Groundbreaking OpenSSH Vulnerability Research
Qualys (QLYS) Wins Two Pwnie Awards at DEF CON for Groundbreaking OpenSSH Vulnerability Research

Yahoo

time4 hours ago

  • Yahoo

Qualys (QLYS) Wins Two Pwnie Awards at DEF CON for Groundbreaking OpenSSH Vulnerability Research

Qualys, Inc. (NASDAQ:QLYS) is one of the Qualys, Inc. (NASDAQ:QLYS) is one of the best midcap AI stocks to buy right now. On August 12, 2025, Qualys announced that its Threat Research Unit (TRU) received two Pwnie Awards at the DEF CON cybersecurity conference for its groundbreaking work uncovering critical OpenSSH vulnerabilities. The awards, 'Epic Achievement' and 'Best Remote Code Execution (RCE)', recognized Qualys for identifying CVE-2024-6387, the first pre-authentication RCE in OpenSSH in nearly two decades, and CVE-2025-26465, a man-in-the-middle attack affecting FreeBSD clients. The wins cement Qualys' status as a major player in vulnerability research. welcomia/ Alongside its ongoing threat research, Qualys expanded coverage within its Enterprise TruRisk Platform on August 12, 2025, issuing new vulnerability checks tied to Microsoft's latest Patch Tuesday update. While the company did not publish a formal press release, its research portal listed 98 vulnerabilities across 12 Microsoft security bulletins, with immediate support deployed for customer environments. The update underscores Qualys' operational emphasis on rapid detection and remediation, reinforcing its reputation for delivering same-day protections aligned with major vendor disclosures. Qualys is a U.S.-based provider of cloud-native IT, security, and compliance solutions. Its platform is used by global enterprises to manage vulnerabilities, ensure policy compliance, protect against threats, and inventory digital assets across hybrid environments. While we acknowledge the potential of QLYS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

SentinelOne (S) Expands Mimecast Partnership to Advance Human-Centric Cybersecurity
SentinelOne (S) Expands Mimecast Partnership to Advance Human-Centric Cybersecurity

Yahoo

time4 hours ago

  • Yahoo

SentinelOne (S) Expands Mimecast Partnership to Advance Human-Centric Cybersecurity

SentinelOne, Inc. (NYSE:S is one of the SentinelOne, Inc. (NYSE:S) is one of the best midcap AI stocks to buy right now. On August 6, 2025, SentinelOne announced an expanded partnership with Mimecast to advance human-centric cybersecurity. The integration connects SentinelOne's Singularity™ Platform with Mimecast's Human Risk Management (HRM) solution, enabling enterprises to correlate endpoint telemetry with behavioral insights and email-based threat intelligence. The goal is to strengthen real-time detection, automate risk scoring, and deliver targeted awareness training based on individual user behavior. Den Rise/ This collaboration marks a shift toward more adaptive, user-aware security frameworks. By analyzing how people interact with their environments, through devices, apps, and communications, the combined solution helps identify at-risk users and prioritize them for intervention. SentinelOne's AI-driven endpoint protection feeds into Mimecast's analytics to uncover patterns of risky behavior, enhancing both detection and prevention efforts. SentinelOne is a California-based cybersecurity company that provides autonomous endpoint protection, cloud security, and identity threat detection through its Singularity™ Platform. The company employs artificial intelligence and machine learning to deliver real-time threat prevention, detection, and response at machine speed. While we acknowledge the potential of S as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and .

Globant (GLOB) Upgrades GEAI Platform with New Protocols to Drive Cross-Platform AI Interoperability
Globant (GLOB) Upgrades GEAI Platform with New Protocols to Drive Cross-Platform AI Interoperability

Yahoo

time4 hours ago

  • Yahoo

Globant (GLOB) Upgrades GEAI Platform with New Protocols to Drive Cross-Platform AI Interoperability

Globant S.A. (NYSE:GLOB) is one of the Globant S.A. (NYSE:GLOB) is one of the best midcap AI stocks to buy right now. On July 31, 2025, Globant unveiled a major upgrade to its Globant Enterprise AI (GEAI) platform, now incorporating Model Context Protocol (MCP) and Agent2Agent (A2A) Protocol capabilities. This update allows seamless interoperability between GEAI and external AI frameworks — from Agentforce and Google Cloud to Azure AI Foundry and Amazon Bedrock — making GEAI a more flexible and integrative foundation for enterprise AI. Copyright: photovibes / 123RF Stock Photo The enhancement boosts enterprises' ability to collaborate across AI systems more fluidly and modernize legacy systems with greater efficiency. By enabling platform-agnostic communication, developers can mix and match models while reducing integration friction. This positions Globant not just as a service provider, but as a connective fabric across complex AI ecosystems. Globant is a Luxembourg-based digital technology company with a core focus on reinvention through AI-powered software solutions. Its end-to-end platform supports everything from agile teams to enterprise-grade AI deployments, helping global clients in sectors like media, tech, and finance bring innovative products to life. While we acknowledge the potential of GLOB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and .

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store